NC Sin, CK Li, MK Shing, KW Chik, PMP Yuen

Abstract

Treatment of life threatening and yet steroid non-responsive Kasabath-Merritt syndrome patient with interferon alpha during infancy is associated with potentially irreversible spastic diplegia. Physicians should balance the risk and benefit of interferon treatment. Repeated clinical assessment of neuro-developmental status is mandatory in those interferon treated infants. Early discontinuation of interferon alpha treatment has the potential of reversal of early onset spastic diplegia.